Favorable Safety, Splicing Trends Emerge for PepGen's Lead Drug PGN-EDODM1
Summary
PepGen reported favorable safety and splicing trends from the 5 mg/kg cohort of its lead drug candidate, PGN-EDODM1, in the FREEDOM2 trial. The drug was generally well-tolerated with all adverse events being mild/moderate and no serious adverse events reported. Promising splicing correction was observed, with a mean of 22.9% for treated patients when an outlier was excluded. This positive data is a significant development for the company, especially following the partial clinical hold on its lead DM1 drug candidate and the discontinuation of its DMD program, as disclosed in its recent 10-K filing. The favorable results could help restore investor confidence and provide a clearer path forward for the program. Investors will now focus on the upcoming 10 mg/kg data readout expected in the second half of 2026, which represents the next major catalyst for the stock.
At the time of this announcement, PEPG was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $292.4M. The 52-week trading range was $0.88 to $7.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.